Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to cosmeceuticals.

The group’s origin can be traced to 1952 when it was founded by Late Mr. Ramanbhai B. Patel, a first-generation entrepreneur and one of the stalwarts of the Indian Pharmaceutical Industry. In 1995, the group restructured its operations and Cadila Healthcare came into being under the aegis of the Zydus group. Zydus Cadila, today, is spearheaded by Mr. Pankaj R. Patel, the Chairman and Managing Director of the group. From a turnover of Rs 2.5 billion in 1995, the group’s turnover soared to  Rs 1900 crores in 2006-07.

Today, Zydus Cadila holds a commanding position in the domestic pharma industry sweepstakes. It is currently the leader in the cardiovascular, gastrointestinal and women’s healthcare segments and has leading positions in other therapeutic segments such as respiratory and pain management. Globally, it is present in the regulated markets of US, Europe, Japan and Latin America besides other emerging markets. It aims to be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020.

Supporting its marketing prowess is the group’s manufacturing facilities. The group has state-of-the-art vertically integrated manufacturing facilities for APIs and formulations, spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim. Of these, three facilities are US FDA approved. The formulation plant at Moraiya, Ahmedabad has received approvals from some of the world’s leading regulatory authorities such as the US FDA, MHRA of U.K., AFSSAPS of France, MCC of South Africa, ANVISA of Brazil, BFAD of Philippines, PIC of Romania and MoH of Latvia and Namibia. The API plant at Ankleshwar has received approvals from US FDA and AFSSAPS from France. The group’s API plant at Dabhasa is also US FDA approved.

The group has a team of more than 500 research professionals spearheading its research and development programme of which 300 scientists alone are involved in the NCE research programme at Zydus Research Centre, the group’s state-of-the-art R&D centre. Within a short span of time, the group has made remarkable progress on the New Chemical Entity (NCE) research and has five INDs in various stages of clinical trials. Zydus Cadila invests nearly 8% of its turnover on research.

Zydus Cadila is supported by a team of over 8000 people worldwide, comprising professionals, research scientists, medical advisors and workers. Poised for a higher growth and more success in the coming years, Zydus Cadila draws confidence from its proven track record, which both prescribes and projects a vibrant and soundly based future.

Website: www.zyduscadila.com